New at WaveTec

Article

Thomas G. Frinzi is to become company President and Chief Executive Officer at WaveTec Vision. He replaces Tom Berryman who after a period of transition will be leaving the company to pursue other entrepreneurial ventures.

Thomas G. Frinzi is to become company President and Chief Executive Officer at WaveTec Vision. He replaces Tom Berryman who after a period of transition will be leaving the company to pursue other entrepreneurial ventures.

“The board appreciates Tom Berryman’s leadership and great contribution to the company's achievements, as well as his role in recruiting Tom Frinzi to the company. We are enormously pleased to welcome Tom to WaveTec,”said Charles Warden, of Versant Ventures a board member and investor in WaveTec. “Tom is a seasoned and dynamic leader who brings a wealth of proven commercial experience within the ophthalmic space. ”

Frinzi who began his career at Johnson & Johnson, is a 30 year veteran of the ophthalmic and medical device industries. Most recently, he served as Vice President of Global Commercial Operations at Bausch+Lomb Surgical where he was responsible for worldwide revenue of approximately $500 million generated via their cataract and vitreo‐retinal product portfolio.

“What attracted me to WaveTec is the potential to change the landscape of cataract surgery,” said Mr Frinzi. “What cornea topography was to refractive surgery, ORange can be to cataract surgery. The Premium Channel has raised expectations and WaveTec is uniquely positioned to help surgeons optimize their outcomes and ultimately improve the overall patient experience. That's exciting.”

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.